$2.67 Billion is the total value of Tekla Capital Management LLC's 204 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 48.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMGN | Sell | Amgen Inc. | $154,585,000 | +7.1% | 608,218 | -0.6% | 5.79% | +5.4% |
| VRTX | Sell | Vertex Pharmaceuticals Inc. | $109,218,000 | -21.2% | 401,360 | -15.9% | 4.09% | -22.4% |
| JNJ | Sell | Johnson & Johnson | $81,408,000 | -30.3% | 546,805 | -34.1% | 3.05% | -31.3% |
| BIIB | Sell | Biogen Inc. | $60,637,000 | -3.0% | 213,753 | -8.5% | 2.27% | -4.5% |
| UNH | Sell | Unitedhealth Group Inc. | $57,907,000 | -29.9% | 185,735 | -33.7% | 2.17% | -31.0% |
| BMY | Sell | Bristol Myers Squibb Co. | $56,982,000 | -0.9% | 945,140 | -3.3% | 2.14% | -2.4% |
| ABT | Sell | Abbott Laboratories | $40,221,000 | -9.5% | 369,573 | -24.0% | 1.51% | -10.9% |
| SYK | Sell | Stryker Corp. | $32,887,000 | +11.1% | 157,830 | -3.9% | 1.23% | +9.4% |
| MRNA | Sell | Moderna, Inc. | $32,570,000 | +3.0% | 460,359 | -6.5% | 1.22% | +1.3% |
| ALXN | Sell | Alexion Pharmaceuticals, Inc. | $30,529,000 | -29.3% | 266,791 | -30.7% | 1.14% | -30.4% |
| LLY | Sell | Eli Lilly and Co. | $26,294,000 | -22.6% | 177,637 | -14.1% | 0.98% | -23.8% |
| CVS | Sell | CVS Health Corp. | $22,675,000 | -51.5% | 388,263 | -46.0% | 0.85% | -52.2% |
| IMMU | Sell | Immunomedics, Inc. | $18,990,000 | +7.8% | 223,336 | -55.1% | 0.71% | +6.1% |
| ISRG | Sell | Intuitive Surgical, Inc. | $17,787,000 | -6.4% | 25,069 | -24.8% | 0.67% | -7.7% |
| DHR | Sell | Danaher Corp. | $14,549,000 | -48.4% | 67,567 | -57.6% | 0.54% | -49.2% |
| INCY | Sell | Incyte Corp. | $13,695,000 | -59.5% | 152,605 | -53.1% | 0.51% | -60.1% |
| IDXX | Sell | IDEXX Laboratories, Inc. | $13,686,000 | +12.0% | 34,814 | -5.9% | 0.51% | +10.3% |
| NVS | Sell | Novartis AGsponsored adr | $13,177,000 | -11.8% | 151,525 | -11.4% | 0.49% | -13.0% |
| TMO | Sell | Thermo Fisher Scientific Inc. | $13,008,000 | -66.1% | 29,461 | -72.2% | 0.49% | -66.7% |
| NVCR | Sell | NovoCure Ltd.ordinary shares | $13,006,000 | +66.6% | 116,845 | -11.2% | 0.49% | +64.0% |
| CI | Sell | Cigna Corp. | $12,069,000 | -19.6% | 71,241 | -10.9% | 0.45% | -20.8% |
| HCA | Sell | HCA Healthcare, Inc. | $10,215,000 | +25.5% | 81,933 | -2.3% | 0.38% | +23.5% |
| ANTM | Sell | Anthem, Inc. | $9,974,000 | -5.8% | 37,133 | -7.7% | 0.37% | -7.2% |
| ZTS | Sell | Zoetis Inc.class a | $9,347,000 | -15.9% | 56,521 | -30.3% | 0.35% | -17.3% |
| BGNE | Sell | BeiGene, Ltd.sponsored adr | $8,101,000 | -42.7% | 28,280 | -62.3% | 0.30% | -43.5% |
| PRAH | Sell | PRA Health Sciences, Inc. | $8,067,000 | -42.2% | 79,526 | -44.6% | 0.30% | -43.1% |
| NBIX | Sell | Neurocrine Biosciences, Inc. | $6,078,000 | -75.8% | 63,203 | -69.3% | 0.23% | -76.2% |
| ABMD | Sell | ABIOMED, Inc. | $3,383,000 | -11.3% | 12,212 | -22.7% | 0.13% | -12.4% |
| EXAS | Sell | Exact Sciences Corp. | $1,545,000 | -59.6% | 15,150 | -65.6% | 0.06% | -60.3% |
| NVAX | Sell | Novavax, Inc. | $1,249,000 | -47.5% | 11,523 | -59.6% | 0.05% | -48.4% |
| GSK | Sell | GlaxoSmithKline PLCshares | $1,220,000 | -86.4% | 32,400 | -85.3% | 0.05% | -86.5% |
| AXNX | Sell | Axonics Modulation Technologies, Inc. | $990,000 | +0.3% | 19,400 | -31.0% | 0.04% | -2.6% |
| TTPH | Exit | Tetraphase Pharmaceuticals, Inc. | $0 | – | -42,965 | -100.0% | -0.00% | – |
| ARPO | Exit | Aerpio Pharmaceuticals, Inc. | $0 | – | -257,554 | -100.0% | -0.01% | – |
| CDTX | Exit | Cidara Therapeutics, Inc. | $0 | – | -195,256 | -100.0% | -0.03% | – |
| PBYI | Exit | Puma Biotechnology, Inc. | $0 | – | -71,340 | -100.0% | -0.03% | – |
| Exit | Innate Pharma SAsponsored ads | $0 | – | -137,734 | -100.0% | -0.03% | – | |
| MNLO | Exit | Menlo Therapeutics Inc. | $0 | – | -541,584 | -100.0% | -0.04% | – |
| RUBY | Exit | Rubius Therapeutics, Inc. | $0 | – | -155,982 | -100.0% | -0.04% | – |
| NTLA | Exit | Intellia Therapeutics, Inc. | $0 | – | -55,050 | -100.0% | -0.04% | – |
| KOD | Exit | Kodiak Sciences Inc. | $0 | – | -23,153 | -100.0% | -0.05% | – |
| BBIO | Exit | BridgeBio Pharma, Inc. | $0 | – | -39,228 | -100.0% | -0.05% | – |
| WVE | Exit | WaVe Life Sciences Ltd.shares | $0 | – | -128,146 | -100.0% | -0.05% | – |
| SGMO | Exit | Sangamo Therapeutics, Inc. | $0 | – | -149,835 | -100.0% | -0.05% | – |
| EVH | Exit | Evolent Health, Inc. | $0 | – | -231,027 | -100.0% | -0.06% | – |
| PACB | Exit | Pacific Biosciences of California, Inc. | $0 | – | -495,495 | -100.0% | -0.06% | – |
| HALO | Exit | Halozyme Therapeutics, Inc. | $0 | – | -69,917 | -100.0% | -0.07% | – |
| PTLA | Exit | Portola Pharmaceuticals, Inc.sponsored adr | $0 | – | -109,246 | -100.0% | -0.08% | – |
| AVRO | Exit | AVROBIO, Inc. | $0 | – | -140,581 | -100.0% | -0.09% | – |
| ANAB | Exit | AnaptysBio, Inc. | $0 | – | -118,261 | -100.0% | -0.10% | – |
| QTNT | Exit | Quotient Ltd. | $0 | – | -411,937 | -100.0% | -0.12% | – |
| GWPH | Exit | GW Pharmaceuticals plcads | $0 | – | -25,051 | -100.0% | -0.12% | – |
| EPZM | Exit | Epizyme, Inc. | $0 | – | -207,752 | -100.0% | -0.13% | – |
| LGND | Exit | Ligand Pharmaceuticals Inc. | $0 | – | -30,590 | -100.0% | -0.13% | – |
| PRNB | Exit | Principia Biopharma Inc. | $0 | – | -60,390 | -100.0% | -0.14% | – |
| MNTA | Exit | Momenta Pharmaceuticals, Inc. | $0 | – | -111,768 | -100.0% | -0.14% | – |
| EDIT | Exit | Editas Medicine, Inc. | $0 | – | -130,201 | -100.0% | -0.15% | – |
| XLRN | Exit | Acceleron Pharma Inc. | $0 | – | -40,606 | -100.0% | -0.15% | – |
| INO | Exit | Inovio Pharmaceuticals, Inc. | $0 | – | -202,038 | -100.0% | -0.21% | – |
| RCKT | Exit | Rocket Pharmaceuticals, Inc. | $0 | – | -289,029 | -100.0% | -0.23% | – |
| PTCT | Exit | PTC Therapeutics, Inc. | $0 | – | -120,827 | -100.0% | -0.23% | – |
| ALLO | Exit | Allogene Therapeutics, Inc. | $0 | – | -216,069 | -100.0% | -0.35% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.